Quoin Pharmaceuticals

IN THE PRESS

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

March 26, 2026

·

13 min read

Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome

March 25, 2026

·

6 min read

Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

March 19, 2026

·

1 min read

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

March 11, 2026

·

5 min read

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

February 26, 2026

·

7 min read

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

January 28, 2026

·

5 min read

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

January 20, 2026

·

6 min read

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

November 11, 2025

·

7 min read

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results

November 7, 2025

·

10 min read

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

October 31, 2025

·

1 min read

JOBS